Company profile
Apoha Limited
Apoha
Materials that absorb intelligence
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Capital Allotment Shares
CapitalSH01 | Transaction MzUxNDEyOTIxMWFkaXF6a2N4
Published 02 Apr 2026 14:48
Accounts filed
AccountsLast accounts made up date
Accounts With Accounts Type Total Exemption Full
Accounts Awaiting analysisAA | Transaction MzQzMjUxMDA1N2FkaXF6a2N4
Published 16 Aug 2024 14:41
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Liquid Brain: Developing a site-deployable neuromorphic sensing and computing platform to revolutionise antibody screening
1 Jun 2025 to 31 Aug 2026
Founded in 2021 by Dr Shamit Shrivastava (experimental physicist and inventor of Apoha's core platform technology; previously postdoctoral researcher at the University of Oxford) and Anshika Srivastava (skilled in operating and scaling businesses; previously Executive Director/Vice President, Goldman Sachs), Apoha is a seed-stage start-up based in London....
Liquid Brain: Revolutionising Antibody-Target Binding and Developability Analysis with Neuromorphic Sensing and Computing
1 Jan 2025 to 30 Jun 2026
For 50 years, the UK has led the world in developing monoclonal antibodies. Today, there are over 100 monoclonal antibodies approved by the US Food and Drug Administration, and the global monoclonal antibody therapeutics market is valued at USD279.8bn (Dimension Market Research). However, efforts to develop novel therapeutics remain stymied by the persist...
Liquid Brain: Revolutionising prediction of the in vivo pharmacokinetics and biodistribution of mRNA-lipid nanoparticles
1 Dec 2024 to 31 May 2026
Lipid nanoparticles (LNPs) are sub-micron-scale spherical vesicles made of ionisable lipids. They are used to safely and effectively deliver drugs including nucleic acids such as messenger RNA (mRNA) to target cells, most prominently being deployed in Pfizer-BioNTech and Moderna's mRNA-based COVID-19 vaccines. Although receiving increasing attention, LNPs...
Apoha: Cross-cutting technology to support adoption of synthetic biology food systems
1 Sep 2023 to 28 Feb 2025
Synthetic biology is poised to revolutionise future food systems, increasing sustainability, affordability, and quality for consumers, while improving resource efficiency and global food security. But, today, synthetic biology start-ups as well as FoodTech and Fast-Moving Consumer Goods innovators looking to integrate synthetic biology ingredients into no...
Liquid Brain: Neuromorphic sensing and computing platform for high-throughput screening of antibody developability
1 Dec 2022 to 31 May 2024
Drug development costs are rising and pharmaceutical R&D efficiency is falling, increasing costs for BioTech and Pharma companies, healthcare providers, and reducing affordability and accessibility for patients worldwide. 90% of drug candidates fail during clinical-stage development. Poor developability accounts for one third of clinical-stage failures of...
Development of the world’s first universal liquid chromatography detector for pharmaceutical applications
1 Jun 2022 to 30 Nov 2023
High-performance liquid chromatography (HPLC) is the most widely used analytical technique in pharmaceutical analysis, with applications spanning from detection of active pharmaceutical ingredients in drug formulations and biological fluids to quality control and assurance; for example, monitoring pharmaceutical impurities and degradation products (Siddiq...